Several studies have found there to be a negative correlation between adiponectin levels and the risk of prostate cancer, suggesting its potential role in inhibiting cancer progression (Hu et al., 2019; Kashiwagi et al., 2024). This evidence concerns the gene ADIPOQ and prostate carcinoma.